Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EarlyDiagnostics logo — A leader in non-invasive genomics, early cancer diagnostics,...

EarlyDiagnostics

A leader in non-invasive genomics, early cancer diagnostics, biomarker & CDx

Founded 2017 United States Los Angeles, United States 8 employees Biotechnology, Health Care

General Information

Company Name EarlyDiagnostics
Founded Year 2017
Location United States Los Angeles, United States
Employees 8
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with EarlyDiagnostics. To contact EarlyDiagnostics, visit earlydx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EarlyDiagnostics compare?

A PDF of EarlyDiagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EarlyDiagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EarlyDiagnostics

EarlyDiagnostics, established in 2017 and headquartered in the United States, is a promising player in the Biotechnology and Health Care sectors. The company positions itself as "A leader in non-invasive genomics, early cancer diagnostics, biomarker & CDx."

With a focus on cfDNA-based technologies, EarlyDiagnostics has developed a suite of innovative tools like cfMethyl-seq, cfSNV, and cfTrack, which are designed to enhance diagnostics accuracy and monitoring capabilities for various diseases, including cancer. These tools are powered by sophisticated AI algorithms, ensuring high precision in biomarker discovery and diagnostics.

Despite its apparent technological prowess, the company has yet to announce its latest round of financing, and key investors remain unnamed. Potential investors might find this an opportune moment to engage, given the company's robust foundation in precision medicine and expanding market potential.

Business keywords: Non-Invasive Genomics, Early Cancer Diagnostics, Biomarker Discovery, Precision Medicine, cfDNA Technologies, cfMethyl-seq, cfSNV, Cancer Monitoring, MRD Detection, AI Algorithms in Genomics, Liquid Biopsy, Bioinformatics Platform, Metabolic Disease Diagnostics, Neurological Disease Diagnostics, Autoimmune Disease Diagnostics

Services & Products

Early cancer detection
Liquid biopsy assays
Bioinformatics solutions
Cancer therapy selection
Cancer treatment monitoring

Target Customers

Diagnostic companies Healthcare providers Biopharmaceutical companies Cancer patients Medical researchers

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Round Undisclosed -
01 Jan 2019

EarlyDiagnostics Alternatives & Competitors

View All Alternatives
EarlyDiagnostics vs
Ophiomics
Ophiomics Portugal

Precision Medicine solutions

Grant
11 employees
Biotechnology, Health Care
EarlyDiagnostics vs
Diatech Pharmacogenetics
Diatech Pharmacogenetics Italy

Leader in the development, production and sales of pharmacogenetics tests for cancer precision medic...

Private Equity
76 employees
Biotechnology, Health Care
EarlyDiagnostics vs
Evvy
Evvy United States

Precision women's healthcare, powered by the vaginal microbiome.

Series A
61 employees
Biotechnology, Health Care
View all alternatives

FAQ About EarlyDiagnostics

A leader in non-invasive genomics, early cancer diagnostics, biomarker & CDx
EarlyDiagnostics was founded in 2017.
EarlyDiagnostics is headquartered in Los Angeles, United States.
EarlyDiagnostics operates in Biotechnology and Health Care. Its work centres on Non-Invasive Genomics, Early Cancer Diagnostics, Biomarker Discovery and Precision Medicine. Its customers include Diagnostic companies, Healthcare providers and Biopharmaceutical companies.
EarlyDiagnostics has approximately 8 employees.
EarlyDiagnostics has completed 1 funding round.
EarlyDiagnostics offers: Early cancer detection, Liquid biopsy assays, Bioinformatics solutions, Cancer therapy selection, Cancer treatment monitoring.
Top alternatives and competitors to EarlyDiagnostics include Ophiomics, Diatech Pharmacogenetics, Evvy, Exai Bio, Paragon Genomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EarlyDiagnostics and Ophiomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EarlyDiagnostics, https://bouncewatch.com/company/earlydiagnostics, updated 3 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes